Chris Easton
SUPPLY CHAIN
“ We could use technology to triage vast numbers of patients and data into more specific diagnosis boxes ”
CHRIS EASTON GLOBAL COMMERCIAL LEAD , TAKEDA
be excessively long and heavy , which has a big impact on their quality of life .
" It ' s a hereditary disorder , so many women in a family can be affected , but it ' s hard to diagnose ", Easton explains . However , using existing technology that tracks the menstrual cycle via a smartphone perhaps an alert can be issued to let the user know when it ' s time to start taking replacement therapy for Von Willebrand . " This means that by the time a period begins , Von Willebrand levels are
Chris Easton
TITLE : SENIOR DIRECTOR , GLOBAL COMMERCIAL LEAD - PERSONALISED HEALTH & INNOVATION , RARE HAEMATOLOGY
COMPANY : TAKEDA INDUSTRY : PHARMA
Chris Easton started his career as a field sales rep in the UK , focused on customer engagement . After moving into marketing , he became EMEA Marketing Manager at Baxter International , a US healthcare company specialising in haemophilia , kidney disease , and immune disorders .
He spent 11 years at Baxter , taking on more and more strategic roles , as well as spending some time in commercial operations . In 2014 he joined Novo Nordisk , where he was the European head for their Biopharm division . After this , he took on a consulting position at Tesaro before GSK acquired it .
In 2017 he joined Shire , leading their portfolio strategy and market development for rare haematology ; in 2019 , the company was acquired by Takeda .
healthcareglobal . com 123